Tendersinfo keep you informed about the latest events in the national and international Procurement Industry. Procurement News provides in-depth coverage of the procurement industry, including contract awards, contract additions, new contract wins, mergers and acquisitions. Tendersinfo through its tender news section provides an update on all domestic and global tendering opportunities, invitation to bid & trade leads.

Publish Date : 19-Nov-2013

German company Merck KGaA will construct a 650 million yuan ($106.67 million) pharmaceutical plant in Nantong, East China's Jiangsu Province. There, the division will focus on producing Merck's heart and metabolic medicines. Once completed, the plant will be the second-largest pharmaceutical plant of Merck Serono, a biopharmaceutical division of the German group.

Merck Serono's largest current pharmaceutical plant is located in Germany.

The Merck plant will be built at an industrial park in Nantong and it will begin production in 2017.

The company will make medicines to treat diabetes, thyroid and cardiovascular diseases in the Nantong plant. All of the drugs produced in the plant are covered by China's essential drug list. Prices of drugs named in the essential list will be lowered to guarantee better access to patients, and those who use listed drugs could enjoy government reimbursement.

"Local production of the drugs could help Merck to lower its costs," Zhong Hongyue, a healthcare sector analyst at consulting firm Frost & Sullivan said.

The bio industry is one of the emerging industries being supported by the Chinese government. In a five-year plan released by the State Council in December 2012, the government has set a target of at least 20 percent annual growth for the biopharmaceutical sector in China from 2013 through 2015. International drug firms have fastened in getting into the growing biopharmaceutical sector. Merck just signed a deal with Beijing-based biotech company BeiGene to cooperate in cancer treatment.

US drug maker Eli Lilly and Co also will invest over $700 million globally in its insulin capacity, of which $350 million will go to China.

China's biopharmaceutical industry has potential for strong growth. Worldwide the sector accounted for 17 percent of the overall drug market by 2010, but the ratio in China has stood at about 5 percent, Joseph Cho, managing director at an industry association representing major international drug firms in China, said at a forum in Beijing. At the forum, Cho has also called for a more optimized regulatory process.

Go to previous page